Conferences

Topics Overview

  • 180-Day Marketing Exclusivity
  • AI in IP
  • Amgen Inc. v. Sanofi, which addressed 35 U.S.C. 112
  • Analyzing the Effect of the Latest FDA Initiatives on Generic Drug Access and PIV Disputes
  • ANDA Litigation: A Comprehensive Analysis
  • GSK v. Teva: Awaiting the Fate of Section VIII Carve-outs
  • Hatch-Waxman Act Evolution: Written description and enablement requirements under 35 U.S.C. § 112 Pharma Patent Disputes
  • Improperly Listed Orange Book Patents – Recent FTC Scrutiny and Strategies for ANDA Filers to Take Advantage
  • Polymorph Patents: Infringement and Invalidity Challenges
  • Recent Hatch-Waxman and BPCIA amendments
  • US Patent Litigation: Advanced Strategies and Rule of Civil Procedure Insights for ANDA Cases
Scroll to Top